New combo therapy aims to boost lung cancer treatment

NCT ID NCT05937906

Recruiting now Disease control Sponsor: Centre Georges Francois Leclerc Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 29 times

Summary

This study tests whether adding a short course of the MEK inhibitor mirdametinib to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer whose PDL1 level is below 50%. About 24 participants will first help find the best dose, then be randomly assigned to receive the new combination or standard treatment. The goal is to improve disease control without requiring lifelong medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Georges-François Leclerc
RECRUITING

Dijon, Burgundy, 21000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER